Inhibitor development in nonsevere hemophilia A
Eckhardt, C.L.

Citation for published version (APA):
Eckhardt, C. L. (2014). Inhibitor development in nonsevere hemophilia A

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
**Name PhD student:** C.L. de Groot – Eckhardt  
**PhD period:** January 2008 – September 2014

### 1. PhD training

#### General Courses
- **Advanced Topics in Clinical Epidemiology**  
  Year: 2010  
  ECTS: 1.1
- **Scientific writing in English for Publication**  
  Year: 2009  
  ECTS: 1.5
- **Cochrane systematic reviews**  
  Year: 2009  
  ECTS: 0.3
- **Communication (UvA)**  
  Year: 2009  
  ECTS: 0.6
- **Good Clinical Practice (BROK)**  
  Year: 2008  
  ECTS: 0.9
- **Practical Biostatistics**  
  Year: 2008  
  ECTS: 1.1
- **Clinical data management**  
  Year: 2008  
  ECTS: 0.2
- **Clinical epidemiology**  
  Year: 2008  
  ECTS: 0.6
- **Evidence Based Searching**  
  Year: 2008  
  ECTS: 0.1
- **Project Management (UvA)**  
  Year: 2008  
  ECTS: 0.6

#### Specific courses
- **Training Upcoming Leaders in Paediatric Science (TULIPS) PhD curriculum**  
  Year: 2011-2012  
  ECTS: 4.0
- **Clinical epidemiology course Schiermonnikoog, dept of clinical epidemiology, LUMC, Leiden**  
  Year: 2011  
  ECTS: 1.5
- **VNVA Kadertraining, Ina Vader, Amersfoort**  
  Year: 2010-2011  
  ECTS: 2.0
- **‘Dag voor de jonge onderzoekers’, NVK, Veldhoven**  
  Year: 2009-2012  
  ECTS: 0.75
- **PhD course hemophilia (2008) and arterial thrombosis (2009) (NVTH)**  
  Year: 2008-2009  
  ECTS: 4.0
- **Advanced course on lab and clinical aspects of hemophilia (NVHP/EKZ/UMCG), Eerbeek, The Netherlands**  
  Year: 2008  
  ECTS: 0.5

#### Seminars, Workshops and Master classes
- **Grant writing course, ZonMW, the Hague**  
  Year: 2012  
  ECTS: 0.5
- **Herfstpalet, Pediatric Hematology, EKZ, Amsterdam**  
  Year: 2009 -2011  
  ECTS: 1.0
- **Immunology afternoon by Polly Matzinger, Sanquin, Amsterdam**  
  Year: 2009  
  ECTS: 0.5
- **Masterclass of the EKZ Symposium, Amsterdam**  
  Year: 2009  
  ECTS: 0.5
- **Workshop on ITI, Brussels, Belgium**  
  Year: 2009  
  ECTS: 0.5
- **NWO talent class creative thinking, NWO, The Hague**  
  Year: 2009  
  ECTS: 0.5
- **Weekly department journal club, dept of Vascular Medicine, AMC**  
  Year: 2008-2014  
  ECTS: 4.0
- **Weekly department clinical education, dept of Vascular Medicine, AMC**  
  Year: 2008-2014  
  ECTS: 4.0
- **Weekly department clinical education, dept of Pediatric Hematology, EKZ**  
  Year: 2008-2014  
  ECTS: 4.0

#### Oral presentations (first author only)
- **Factor VIII gene (F8) Mutation and Inhibitor Development in Non-Severe Hemophilia A. XXIV ISTH Congress, Amsterdam, The Netherlands.**  
  Year: 2013  
  ECTS: 0.5
- **Inhibitor formation in nonsevere hemophilia A. 5th Inhibitor symposium, Nijmegen, The Netherlands.**  
  Year: 2013  
  ECTS: 0.5
- **INSIGHT in inhibitors in non-severe hemophilia A. 6th annual EAHAH Congress, Warsaw, Poland.**  
  Year: 2013  
  ECTS: 0.5
- **Polymorphism 131R>H in the FCGR2A gene is associated with inhibitor development in Hemophilia A.**  
  Year: 2013  
  ECTS: 0.5
Inhibitor development in mild and moderate hemophilia A. XXX WFH Congress, Paris, France. 2012 0.5

Sevenfold risk for inhibitors in mild/moderate hemophilia A with factor VIII missense mutations in two distinct regions. 31st NVK symposium, Veldhoven, The Netherlands. 2009 0.5

Inhibitor development in mild and moderate hemophilia A seems to be associated with an increased mortality risk. XXIII ISTH Congress, Kyoto, Japan. 2011 0.5

Factor VIII light chain mutations and cysteine substitutions predispose for inhibitor development in mild and moderate hemophilia A: first results from the INSIGHT study. NVTH symposium, Koudekerke, The Netherlands. 2009 0.5

Insight study: International study on etiology of inhibitors in patients with a moderate or mild form of hemophilia A, influences of immunogenetic & hemophilia treatment factors. 4th Inhibitor Symposium, Nijmegen, The Netherlands. 2009 0.5

Poster presentations (first author only)

Clinical presentation of inhibitor development in nonsevere haemophilia A. XXXI WFH Congress, Melbourne, Australia. 2014 0.5

Identification of 18 High Risk F8 Mutations for Inhibitor Development in 2,700 Non-Severe Hemophilia A Patients. XXX WFH Congress, Paris, France. 2012 0.5

Wide variation in factor VIII plasma levels in mild and moderate hemophilia A patients with the same missense mutation is presently unexplained. XXIII ISTH Congress, Kyoto, Japan. 2011 0.5

Factor VIII light chain mutations and cysteine substitutions predispose for inhibitor development in mild and moderate hemophilia A: first results from the INSIGHT study. NVTH symposium, Koudekerke. 2010 0.5

New INSIGHT in inhibitor development in mild/moderate hemophilia A: inhibitors arise after more exposure days than in severe disease. XXIX WFH congress, Buenos Aires, Argentine. 2010 0.5

Treatment & its complications in mild and moderate hemophilia A: three decades of experience; first results of a European cohort study (INSIGHT). XXIX WFH congress. Buenos Aires, Argentine. 2010 0.5

Surgery and inhibitor development in hemophilia A: a systematic review. XXIX WFH congress. Buenos Aires, Argentine. 2010 0.5

Factor VIII light chain mutations and cysteine substitutions predispose for inhibitor development in mild and moderate hemophilia A:
first results from the INSIGHT study. NVTH symposium, Koudekerke.  
New INSIGHT in inhibitor development in mild/moderate hemophilia A: inhibitors arise after more exposure days than in severe disease. XXIX WFH congress, Buenos Aires, Argentina.  
Intensive peri-operative use of factor VIII and the Arg593→Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. XXII ISTH Congress. Boston, USA. 
Hematology Conference. Riga, Latvia.

Conferences
6th annual congress of the European Association for Haemophilia and Allied Disorders (EAHAD). Warsaw, Poland. 2013 0.25
Amsterdam Kinderziekenhuis Symposium (AKS), Amsterdam, The Netherlands. 2011,12,14 0.75
Rodin symposium, Amsterdam, The Netherlands. 2011 0.25
7th Global Forum, WFH, Montreal, Canada. 2011 0.5
1st Pediatric: Peri-operative; Sanquin, Amsterdam, The Netherlands. 2011 0.25
Van Creveld Symposium, Utrecht, The Netherlands. 2011 0.25
XXIII International Society of Thrombosis and Haemostasis (ISTH) Congress, Kyoto, Japan. 2011 1.25
Global Nurse Symposium, Zurich, Switzerland. 2011 0.25
XXIX WFH Congress, Buenos Aires, Argentine. 2010 1.25
Hematology conference, Athens, Greece. 2010 0.75
Hematology conference, Riga, Latvia. 2009 0.75
XXII ISTH Congress, Boston, USA. 2009
Dutch Society on Pediatrics (NVK) symposium, Veldhoven, The Netherlands. 2009,11,12 0.75
Inhibitor symposium, Nijmegen, The Netherlands. 2009, 2013 0.5
Emma Children’s Hospital (EKZ) symposium, Amsterdam, The Netherlands. 2008-10 1.0
Dutch Society on Thrombosis and Haemostasis (NVTH) Symposium, Koudekerke, The Netherlands. 2008-2011 0.75
1st annual congress of the EAHAD, Amsterdam, The Netherlands. 2008 0.25
XXVIII WFH Congress, Istanbul, Turkey. 2008 1.25

2. Teaching
Lecturing
Risk factors for inhibitor development. Haemophilia and Rare Bleeding Disorders Training Camp. Kopenhagen, Denmark. 2012 0.5
Inhibitors: predict, prevent & treat. Global Nurse Symposium. Zurich, Switzerland. 2011 0.5
Inhibitor development in mild and moderate hemophilia A. Baxter and Sanquin symposium, ISTH conference. Boston, USA. 2009 0.5
Supervising

Annieke van Baar, master thesis 2011-2012 1.0
Esmée Krouwel, scientific internship 2011 1.0
Bo van Tienoven, master thesis 2011 1.0
Charlotte Kruit, master thesis 2011 1.0
Albert Jansen, scientific internship 2011 1.0
Alessia van Eijkelenburg, master thesis 2010-2011 1.0
Olivier Rijssenbeek, scientific internship 2009-2010 1.0
Joy van der Pol, scientific internship 2009-2010 1.0
Nina Strecker, master thesis 2009-2010 1.0
Mira van der Naald, master thesis 2009 1.0

Other

Consultant coagulation, lipid disorders and hypertension, dept of Vascular Medicine, Academic Medical Center Amsterdam, the Netherlands 2008-2009
Organisation of INSIGHT study investigator meetings in Istanbul (’08), San Francisco (’08), Boston (’09) and Buenos Aires (’10) 2008-2010

3. Parameters of esteem

Grants, awards and prizes

Young researchers award, XXX WFH Congress, Paris, France 2012
Science Prize, The Netherlands Society on Thrombosis and Hemostasis, Koudekerke, the Netherlands 2011
Young Investigators Award, XXIII ISTH Congress, Kyoto, Japan 2011
ZonMw Agiko Stipendium (nr. 92003551), The Hague, the Netherlands 2009